BFM
NRIX icon

Boothbay Fund Management’s Nurix Therapeutics NRIX Stock Holding History

Boothbay Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-69,134
Closed -$1.55M – 1793
2024
Q3 		$1.55M Sell
69,134
-47,994
-41% -$1.09M 0.04% 606
2024
Q2 		$2.44M Buy
117,128
+37,358
+47% +$582K 0.06% 438
2024
Q1 		$1.17M Buy
+79,770
New +$858K 0.02% 704

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's NRIX Position: Q4 2024 in Review

Boothbay Fund Management sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 69,134 shares — an estimated $1.55M sold.

Boothbay Fund Management first reported a position in NRIX in Q1 2024 and held it in 3 quarters. The position peaked at $2.44M in Q2 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Boothbay Fund Management reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 69,134 Nurix Therapeutics shares in Q4 2024, an estimated $1.55M.
  • Boothbay Fund Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 3 quarters.
  • Boothbay Fund Management's Nurix Therapeutics position peaked at $2.44M in Q2 2024.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Boothbay Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.